RxDoctor Payments Data

Jennifer Lazzara, APRN

Nurse Practitioner · Spokane Valley, WANPI 1720503881

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (37.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Myriad Genetic Laboratories, Inc. accounts for 74.4% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $4,042 and has fallen 61.1% since, to $1,572 in 2025. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,358in general payments, 2019–2025

Across 158 payments — averaging $71.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$8K
  • AstraZeneca$373
  • Sanofi$285
  • Tactile Systems Technology Inc$276
  • Seagen Inc.$213
  • Pfizer$196
  • plus $2K from 25 others

What the payments were for

  • Consulting fees$2,62523%
  • Speaking & faculty fees$3,72533%
  • Travel & lodging$4834%
  • Food & beverage$4,22737%
  • Education$2993%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,358 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$24,042
Medicare patients
178
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Exemestane12$555
Tamoxifen Citrate14$506
Letrozole16$437
Anastrozole25$338

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Spokane Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →